Theravectys
Lentiviral vector vaccine candidates for cancers and chronic infectious diseases, developed with Institut Pasteur
Highlights
- New on EvolcAdded 2026-11-02
About Theravectys
TheraVectys develops lentiviral vector-based vaccine candidates and immunotherapies for the prevention and treatment of cancers and chronic infectious diseases. Its platform targets dendritic cells to trigger T-cell and antibody immune responses, and its pipeline covers oncology, therapeutic and prophylactic infectious disease, and emerging diseases.
The company describes itself as a clinical-stage biotechnology company and a partner of Institut Pasteur. It holds exclusive global licensing agreements covering foundational patents for its platform, and states that it has invested over €100 million in the platform. Its portfolio includes 19 product candidates at various stages of development.
The company is registered in France, in Evry-Courcouronnes, and was founded in 2005. Its management team is led by a Chairman and Chief Executive Officer, with a Chief Scientific Officer heading the TheraVectys Laboratory.
Product: Lentiviral vector-based prophylactic and therapeutic vaccine candidates and immunotherapies.
Jobs at Theravectys
Leadership
- Jean-Marc Loiseau · Executive Director and Vice President of Investor RelationsSource: company website
More biotech & pharma companies
Tissium
Biomorphic programmable polymers for tissue reconstruction in surgery, developed for medtech and surgical useNew on EvolcUPSA
French pharmaceutical laboratory making self-medication drugs, dietary supplements and medical devices for patients and pharmacistsUrosphere
Preclinical research models and drug-development services for pharmaceutical and biotechnology researchersNew on EvolcValerio Therapeutics
Develops precision-targeted antibody therapies for complex and underserved diseasesNew on EvolcValneva
Develops, manufactures and commercializes preventive vaccines for infectious diseases for healthcare professionals and travelersNew on EvolcSalary transparentVaxinano
Vaccine and antigen delivery platform for veterinary and human infectious diseases, including zoonosesNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Hosting
- ApacheHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
- Response headerserver
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.